Abstract
Purpose Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and is a standard second-line therapy ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
